• Citer

Present and future breast cancer management-bench to bedside and back: A positioning paper of academia, regulatory authorities and pharmaceutical industry

par Bartsch, Rupert;Berghoff, Anna Sophie;Zielinski, Christoph C;Gnant, Michael;Frings, Stefan;Marty, Michel;Awada, Ahmad ;Conte, PierFranco;Dickin, S.;Enzmann, Harald;Hasmann, Max;Hendriks, Hans H.R.;Llombart, Antonio;Massacesi, Cristian;Von Minckwitz, Gunter;Pénault-Llorca, Frederique;Scaltriti., Maurizio;Yarden, Yosef;Zwierzina, Heinz
Référence Annals of oncology, 25, 4, page (773-780), mdt531
Publication Publié, 2014

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Present and future breast cancer management-bench to bedside and back: A positioning paper of academia, regulatory authorities and pharmaceutical industry
Auteur:	Bartsch, Rupert; Berghoff, Anna Sophie; Zielinski, Christoph C; Gnant, Michael; Frings, Stefan; Marty, Michel; Awada, Ahmad; Conte, PierFranco; Dickin, S.; Enzmann, Harald; Hasmann, Max; Hendriks, Hans H.R.; Llombart, Antonio; Massacesi, Cristian; Von Minckwitz, Gunter; Pénault-Llorca, Frederique; Scaltriti., Maurizio; Yarden, Yosef; Zwierzina, Heinz
Informations sur la publication:	Annals of oncology, 25, 4, page (773-780), mdt531
Statut de publication:	Publié, 2014
Sujet CREF:	Hématologie
	Cancérologie
Mots-clés:	Biological subtypes
	Breast cancer
	HER2-positive disease
	Luminal disease
	Triple-negative disease
MeSH keywords:	Clinical Trials as Topic
	Female
	Humans
	Molecular Targeted Therapy
	Receptor, ErbB-2 -- genetics
	Signal Transduction
	Triple Negative Breast Neoplasms -- classification -- genetics -- pathology -- therapy
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mdt531
	info:pii/mdt531
	info:scp/84897035109
	info:pmid/24351401